Mechanism Underlying the Reversal of Drug Resistance in P-Glycoprotein-Expressing Leukemia Cells by Pinoresinol and the Study of a Derivative
Open Access
- 25 April 2017
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 8, 205
Abstract
P-glycoprotein (P-gp) is a membrane protein associated with multidrug resistance (MDR) due to its key role in mediating the traffic of chemotherapeutic drugs outside cancer cells, leading to a cellular response that hinders efforts toward successful therapy. With the aim of finding agents that circumvent the MDR phenotype mediated by P-gp, 15 compounds isolated from native and naturalized plants of Argentina were screened. Among these, the non-cytotoxic lignan (±) pinoresinol successfully restored sensitivity to doxorubicin from 7 μM in the P-gp overexpressed human myelogenous leukemia cells, Lucena 1. This resistance-reversing effect was confirmed by competitively increasing the intracellular doxorubicin accumulation and by significantly inhibiting the efflux of doxorubicin and, to a lesser extent, that of rhodamine 123. The activity obtained was similar to that observed with verapamil. No such results were observed in the sensitive parental K562 cell line. To gain deeper insight into the mode of action of pinoresinol, its effect on P-gp function and expression was examined. The lignan bound to P-gp at the apex of the V-shaped transmembrane cavity, involving transmembrane helices 4, 5 and 6, and partially overlapped the binding region of tariquidar, which was used as a positive control. These results would shed some light on the nature of its interaction with P-gp at molecular level and merit further mechanistic and kinetic studies. In addition, it showed a maximum 29% activation of ATP hydrolysis and antagonized verapamil-stimulated ATPase activity with an IC50 of 20.9 μM. On the other hand, pinoresinol decreased the presence of P-gp in the cell surface. Derivatives of pinoresinol with improved activity were identified by docking studies. The most promising one, the non-cytotoxic 1-acetoxypinoresinol, caused a reversion of doxorubicin resistance from 0.11 μM and thus higher activity than the lead compound. It also caused a significant increase in doxorubicin accumulation. Results were similar to those observed with verapamil. The results obtained positioned these compounds as potential candidates for effective agents to overcome P-gp-mediated MDR, leading to better outcomes for leukemia chemotherapy.Keywords
This publication has 90 references indexed in Scilit:
- Understanding the interactions between metabolites isolated from Achyrocline satureioides in relation to its antibacterial activityPhytomedicine, 2013
- Intracellular trafficking of P-glycoproteinThe International Journal of Biochemistry & Cell Biology, 2012
- Secondary Metabolites from Plants Inhibiting ABC Transporters and Reversing Resistance of Cancer Cells and Microbes to Cytotoxic and Antimicrobial AgentsFrontiers in Microbiology, 2012
- The P-glycoprotein multidrug transporterEssays in Biochemistry, 2011
- Rab4 interacts with the human P‐glycoprotein and modulates its surface expression in multidrug resistant K562 cellsInternational Journal of Cancer, 2010
- Characterization of an Asymmetric Occluded State of P-glycoprotein with Two Bound NucleotidesJournal of Biological Chemistry, 2010
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityJournal of Computational Chemistry, 2009
- Targeting multidrug resistance in cancerNature Reviews Drug Discovery, 2006
- Schisandrin B—A novel inhibitor of P-glycoproteinBiochemical and Biophysical Research Communications, 2005
- VMD: Visual molecular dynamicsJournal of Molecular Graphics, 1996